Bms-488043 → Alfa-oxo-1H-pyrrolo-[2,3B]pyridine-3-acetic acid monopotassium salt

HRID 20209Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 20209
C(N1CCN(C(=O)C(C2C3C(=C(OC)N=CC=3OC)NC=2)=O)CC1)(=[O:8])C1C=CC=CC=1.C(N1CCN([C:46](=[O:58])[C:47]([C:49]2[C:57]3[C:52](=[N:53][CH:54]=[CH:55][CH:56]=3)[NH:51][CH:50]=2)=[O:48])[C@H](C)C1)(=O)C1C=CC=CC=1.COC1C=NC(OC)=C2C=1C(C(=O)C([O-])=O)=CN2.[K+:78]>>[NH:51]1[C:52]2[C:57](=[CH:56][CH:55]=[CH:54][N:53]=2)[C:49]([C:47](=[O:48])[C:46]([O-:58])=[O:8])=[CH:50]1.[K+:78]

Komponenten

4

Edukt 3

HCID 507806Bms-488043HCID 5495793Piperazine, 4-benzoyl-1-(1,2-dioxo-2-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-2-methyl-, (2R)-HCID 22893810Potassium (4,7-dimethoxy-6-azaindol-3-yl)-oxoacetate

Produkt 1

HCID 23721194Alfa-oxo-1H-pyrrolo-[2,3B]pyridine-3-acetic acid monopotassium salt

Versuchsvorschrift

Compound IVa, N-(benzoyl)-N′-[(4,7-dimethoxy-6-azaindol-3-yl)-oxoacetyl]piperazine, was prepared by the same method used to prepare compound 5a but the starting material was Potassium (4,7-dimethoxy-6-azaindol-3-yl)-oxoacetate. The compound was purified by silica gel chromatography using EtOAc as the eluting solvent to give a white solid. 1H NMR (500 MHz, DMSO-d6) δ 13.0 (s, 1H), 8.15 (s, 1H), 7.40 (m, 6H), 4.00 (s, 3H), 3.83 (s, 3H), 3.63-3.34 (m, 8H); 13C NMR (125 MHz, DMSO-d6) δ 185.5, 169.3, 166.5, 146.2, 145.7, 136.6, 135.3, 129.6, 128.4, 126.9, 122.2, 122.1, 119.2, 114.4, 56.8, 52.9, 45.5, 39.9. MS m/z: (M+H)+ calcd for C22H23N4O5: 423.17; found 423.19. HPLC retention time: 1.33 minutes (column B). Anal. Calcd. For C22H21N4O5: C, 62.7; H, 5.02; N, 13.29. Found: C, 61.92; H, 5.41; 13.01. Melting Point: 229.5-232° C.

Aufarbeitung

  1. customThe compound was purified by silica gel chromatography
  2. customto give a white solid

Quellen und Nachweise

ORD-Eintrag
ord-53fde10c0a8d49a3b3d7f84cae989aa0
Quelldatensatz
uspto-grants-2010_06
Patentnummer
US07745625B2

Notizen zur Reaktion

Wird geladen…